Oncolytics Biotech (ONCY) Interest Coverage Ratio (2019 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Interest Coverage Ratio of 443.0 for Q3 2025, down 96.08% year-over-year from 11300.07 in Q3 2024, and down 133.09% quarter-over-quarter from 190.06 in Q2 2025.
Oncolytics Biotech (ONCY) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Interest Coverage Ratio for 7 consecutive years, with 443.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Interest Coverage Ratio fell 96.08% year-over-year to 443.0; the TTM figure through Sep 2025 stood at 267.23 (up 59.91% YoY), while the FY2025 annual figure was 0.72, down 1.45% from the prior year.
- Interest Coverage Ratio slipped to 443.0 in Q3 2025 per ONCY's latest filing, from 190.06 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 299.34 in Q2 2021 and bottomed at 2858.17 in Q4 2023.
- Historically, Interest Coverage Ratio has averaged 350.74 across 5 years, with a median of 190.06 in 2025.
- Annual changes were most pronounced in 2021 — Interest Coverage Ratio soared 164.03% — and 2023, when it sank 1079.85%.
- Oncolytics Biotech's Interest Coverage Ratio stood at 1714.46 in 2021, then jumped by 117.01% to 291.69 in 2022, then tumbled by 1079.85% to 2858.17 in 2023, then soared by 93.04% to 198.85 in 2024, then tumbled by 122.78% to 443.0 in 2025.
- Business Quant data shows ONCY's Interest Coverage Ratio at 443.0 in Q3 2025, 190.06 in Q2 2025, and 198.85 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.79 |
| Sep 30, 2025 | -443.00 |
| Jun 30, 2025 | -190.06 |
| Dec 31, 2024 | -198.85 |
| Sep 30, 2024 | -225.93 |
| Jun 30, 2024 | -169.50 |
| Dec 31, 2023 | -2,858.17 |
| Sep 30, 2023 | -131.76 |
| Jun 30, 2023 | -99.61 |
| Mar 31, 2023 | -66.08 |
| Dec 31, 2022 | 291.69 |
| Sep 30, 2022 | -217.95 |
| Jun 30, 2022 | -232.60 |
| Mar 31, 2022 | 288.12 |
| Dec 31, 2021 | -1,714.46 |
| Sep 30, 2021 | 174.16 |
| Jun 30, 2021 | 299.34 |
| Mar 31, 2021 | -467.90 |
| Dec 31, 2020 | 2,043.43 |
| Sep 30, 2020 | -378.35 |